Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial [Rapid Communication]

Conclusion
Results support Rd continuous treatment as a new standard of care for stem-cell transplantation–ineligible patients with newly diagnosed MM of all ages.

Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Hulin, Belch, Shustik, Petrucci, Duhrsen, Lu, Song, Rodon, Pegourie, Garderet, Hunter, Azais, Eek, Gisslinger, Macro, Dakhil, Goncalves, LeBlanc, Romeril, Royer, Doyen, Leleu, Offner, Leupin, Houck, Chen, Ervin-Haynes, Dimopoulos, Facon Tags: Chemotherapy, Biology & Immunology, Rapid Communications Source Type: research